|
|
|
40
|
B4911
|
XOLAIR 150MG INJ (NVS/COL) OMALIZUMAB
|
OMALIZUMAB
|
XOLAIR
|
150MG VIAL
|
C
|
1,304.93
|
1,304.93
|
INJECTION
|
0
|
VIAL
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
COLLINS LTD
|
|
4810
|
RESPIRATORY INFLAMMATORY AGENTS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
41
|
B4911
|
XOLAIR 150MG INJ (NVS) OMALIZUMAB (C)
|
OMALIZUMAB
|
XOLAIR
|
150MG VIAL
|
C
|
1304.93
|
1304.9314
|
VIAL
|
0
|
VIAL
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
COLLINS LTD
|
|
4810
|
RESPIRATORY INFLAMMATORY AGENTS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
RESPIRATORY INFLAMMATORY AGENTS
|
|
|
|
|
40
|
B4913
|
OMALIREL 150MG INJ (RLS/AHI) OMALIZUMAB
|
OMALIZUMAB
|
OMALIREL
|
150MG VIAL
|
C
|
844.86
|
844.86
|
INJECTION
|
0
|
VIAL
|
RLS
|
RELIANCE LIFE SCIENCES
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
4810
|
RESPIRATORY INFLAMMATORY AGENTS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
41
|
B4913
|
OMALIREL 150MG INJ (RLS) OMALIZUMAB (C)
|
OMALIZUMAB
|
OMALIREL
|
150MG VIAL
|
C
|
844.86
|
844.8551
|
VIAL
|
0
|
VIAL
|
RLS
|
RELIANCE LIFE SCIENCES
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
4810
|
RESPIRATORY INFLAMMATORY AGENTS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
RESPIRATORY INFLAMMATORY AGENTS
|
|
|
|
|
40
|
B5012
|
ANORO ELLIPTA 55/22 INHR (GSK/COL) UMECLIDINI
|
UMECLIDINIUM|VILANTEROL
|
ANORO ELLIPTA
|
30 DOSES
|
BQ
|
141.60
|
141.60
|
INHALER
|
1
|
INHR
|
GSK
|
GLAXOSMITHKLINE
|
COL
|
COLLINS LTD
|
|
4892
|
RESPIRATORY AGENTS MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
ORAL INHALATION
|
6
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
41
|
B5012
|
ANORO ELLIPTA 55MCG|22MCG INHR (GSK) UMECLIDINIUM|VILANTEROL (BQ)
|
UMECLIDINIUM|VILANTEROL
|
ANORO ELLIPTA
|
30 DOSES
|
BQ
|
108.68
|
108.6786
|
INHR
|
1
|
BOX
|
GSK
|
GLAXOSMITHKLINE
|
COL
|
COLLINS LTD
|
|
4892
|
RESPIRATORY AGENTS MISCELLANEOUS
|
2024-04-01
|
2024-07-16
|
|
ORAL INHALATION
|
6
|
RESPIRATORY AGENTS MISCELLANEOUS
|
2024-07-16
|
|
|
|
41
|
B5012
|
ANORO ELLIPTA 55MCG|22MCG INHR (GSK) UMECLIDINIUM|VILANTEROL (BQ)
|
UMECLIDINIUM|VILANTEROL
|
ANORO ELLIPTA
|
30 DOSES
|
BQ
|
163.94
|
163.94
|
INHR
|
1
|
BOX
|
GSK
|
GLAXOSMITHKLINE
|
COL
|
COLLINS LTD
|
|
4892
|
RESPIRATORY AGENTS MISCELLANEOUS
|
2024-07-17
|
2026-03-31
|
|
ORAL INHALATION
|
6
|
RESPIRATORY AGENTS MISCELLANEOUS
|
2024-07-17
|
|
|
|
41
|
B521D
|
SAFEBO 125MG TAB (MSN) (BQ)
|
BOSENTAN
|
SAFEBO
|
60'S
|
BQ
|
163.24
|
2.7206
|
TAB
|
0
|
BOX
|
MSN
|
MSN LABS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
4848
|
VASODILATING AGENTS MISCELLANEOUS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
0
|
VASODILATING AGENTS MISCELLANEOUS
|
|
|
|
|
40
|
B521E
|
SAFEBO 62.5MG TAB (MSN/ATB)
|
BOSENTAN
|
SAFEBO
|
60'S
|
BQ
|
163.10
|
2.72
|
TABLET
|
0
|
TAB
|
MSN
|
MSN LABS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
4848
|
VASODILATING AGENTS MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
41
|
B521E
|
SAFEBO 62.5MG TAB (MSN) (BQ)
|
BOSENTAN
|
SAFEBO
|
60'S
|
BQ
|
163.24
|
2.7206
|
TAB
|
60
|
BOX
|
MSN
|
MSN LABS
|
ATB
|
ANSA TRADING BARBADOS LTD
|
|
4848
|
VASODILATING AGENTS MISCELLANEOUS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
VASODILATING AGENTS MISCELLANEOUS
|
|
|
|
|
40
|
B521F
|
PMS-BOSENTAN 125MG TAB (PMS/COL)
|
BOSENTAN
|
PMS-BOSENTAN
|
60'S
|
BQ
|
339.79
|
5.66
|
TABLET
|
0
|
TAB
|
PMS
|
PHARMASCIENCE
|
COL
|
COLLINS LTD
|
|
4848
|
VASODILATING AGENTS MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
40
|
B5312
|
CANCIDAS 50MG INJ (MSD/STO) CASPOFUNGIN
|
CASPOFUNGIN
|
CANCIDAS
|
50MG VIAL
|
C
|
712.77
|
712.77
|
INJECTION
|
0
|
VIAL
|
MSD
|
MERCK SHARP & DOHME (I.A.) CORP
|
STO
|
BRYDEN STOKES LTD
|
|
081416
|
ECHINOCANDINS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTI-INFECTIVE AGENTS
|
|
|
|
|
41
|
B5312
|
CANCIDAS 50MG INJ (MSD) CASPOFUNGIN (BQ)
|
CASPOFUNGIN
|
CANCIDAS
|
50MG VIAL
|
BQ
|
660.74
|
660.743
|
VIAL
|
16
|
VIAL
|
MSD
|
MERCK SHARP & DOHME (I.A.) CORP
|
STO
|
BRYDEN STOKES LTD
|
|
081492
|
ANTIFUNGALS, MISCELLANEOUS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
ANTIFUNGALS, MISCELLANEOUS
|
|
|
|
|
41
|
B5318
|
CANCIDAS 70MG INJ (MSD) CASPOFUNGIN (BQ)
|
CASPOFUNGIN
|
CANCIDAS
|
1 DS VIAL
|
BQ
|
839.96
|
839.9621
|
VIAL
|
1
|
VIAL
|
MSD
|
MERCK SHARP & DOHME (I.A.) CORP
|
STO
|
BRYDEN STOKES LTD
|
|
081492
|
ANTIFUNGALS, MISCELLANEOUS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
ANTIFUNGALS, MISCELLANEOUS
|
|
|
|
|
40
|
B5319
|
CASPOGIN 50MG INJ (CIP/AHI) CASPOFUNGIN
|
CASPOFUNGIN
|
CASPOGIN
|
10ML VIAL
|
BQ
|
335.28
|
335.28
|
INJECTION
|
0
|
VIAL
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
081416
|
ECHINOCANDINS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTI-INFECTIVE AGENTS
|
|
|
|
|
40
|
B5831
|
APO-NABILONE 1MG CAP (APO/COL)
|
NABILONE
|
APO-NABILONE
|
50'S
|
A
|
66.00
|
1.32
|
CAPSULE
|
30
|
CAP
|
APO
|
APOTEX INC.
|
COL
|
COLLINS LTD
|
|
9200
|
UNCLASSIFIED THERAPEUTIC AGENTS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
UNCLASSIFIED THERAPEUTIC AGENTS
|
|
|
|
|
40
|
B5832
|
APO-NABILONE 0.25MG CAP (APO/COL)
|
NABILONE
|
APO-NABILONE
|
50'S
|
A
|
23.05
|
0.46
|
CAPSULE
|
30
|
CAP
|
APO
|
APOTEX INC.
|
COL
|
COLLINS LTD
|
|
9200
|
UNCLASSIFIED THERAPEUTIC AGENTS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
UNCLASSIFIED THERAPEUTIC AGENTS
|
|
|
|
|
40
|
B5911
|
AMLOTENSIVE CT 5MG | 25MG TAB (CAR/COL) AMLODIPINE | CHLORTHALIDONE
|
AMLODIPINE|CHLORTHALIDONE
|
AMLOTENSIVE CT
|
210'S
|
A
|
26.26
|
0.13
|
TABLET
|
60
|
TAB
|
CAR
|
CARLISLE LABORATORIES LTD
|
COL
|
COLLINS LTD
|
B
|
240892
|
HYPOTENSIVE AGENTS, MISCELLANEOUS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
41
|
B5911
|
AMLOTENSIVE CT 5MG|25MG TAB (CAR) AMLODIPINE|CHLORTHALIDONE
|
AMLODIPINE|CHLORTHALIDONE
|
AMLOTENSIVE CT
|
210'S
|
A
|
26.26
|
0.125
|
TAB
|
60
|
BOTT
|
CAR
|
CARLISLE LABORATORIES LTD
|
COL
|
COLLINS LTD
|
B
|
242892
|
CCBs, MISCELLANEOUS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
CCBs, MISCELLANEOUS
|
|
|
|
|
40
|
B5921
|
AMLOTENSIVE CT 5MG | 50MG TAB (CAR/COL) AMLODIPINE | CHLORTHALIDONE
|
AMLODIPINE|CHLORTHALIDONE
|
AMLOTENSIVE CT
|
210'S
|
A
|
35.90
|
0.17
|
TABLET
|
30
|
TAB
|
CAR
|
CARLISLE LABORATORIES LTD
|
COL
|
COLLINS LTD
|
B
|
240892
|
HYPOTENSIVE AGENTS, MISCELLANEOUS
|
2022-07-11
|
2024-03-31
|
Add to Contract as Cat A
|
Oral
|
6
|
CARDIOVASCULAR DRUGS
|
2022-07-11
|
